Physician profile
Sanjaykumar B Shah
NPI 1740226505
$8,408.73
in general payments reported to CMS, 2019-2025
37 companies · $1,492 in 2025
The $1,492 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,075 · 2020: $604 · 2021: $431 · 2022: $1,243 · 2023: $1,308 · 2024: $1,255 · 2025: $1,492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,994 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,994.36 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,620.86 | 2019-2025 | Vraylar, Linzess, Qulipta |
| Glaxosmithkline, LLC. | $1,042.50 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $809.43 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $600.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $529.73 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $491.04 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $395.76 | 2019-2025 | Belsomra, Steglatro, Prevymis |
| Allergan, INC. | $382.68 | 2019-2020 | |
| Astellas Pharma US INC | $332.53 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.39 | 2019-2025 | Jardiance, Synjardy |
| Amgen INC. | $229.35 | 2019-2023 | Evenity, Prolia |
| Takeda Pharmaceuticals U.S.A., INC. | $171.72 | 2019-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $166.71 | 2019-2022 | |
| Abbott Laboratories | $143.61 | 2023-2025 | Freestyle Libre 3 |
| Daiichi Sankyo INC. | $142.73 | 2020-2023 | Injectafer |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $128.81 | 2022 | |
| Sanofi-Aventis U.S. LLC | $123.70 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $104.97 | 2024-2025 | Voquezna |
| Axsome Therapeutics, INC. | $72.42 | 2025 | Auvelity |
| Amarin Pharma, INC. | $71.78 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $56.02 | 2024-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.40 | 2019 | |
| Novartis Pharmaceuticals Corporation | $49.60 | 2019-2025 | |
| Exact Sciences Corporation | $49.20 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Itamar Medical INC | $47.66 | 2024-2025 | Watchpatone |
| Lundbeck LLC | $40.23 | 2025 | Rexulti |
| Pharmacyclics LLC, An Abbvie Company | $30.53 | 2023 | Imbruvica |
| Shield Therapeutics INC | $30.01 | 2024-2025 | |
| Corcept Therapeutics | $28.24 | 2025 | Korlym |
| Biohaven Pharmaceuticals, INC. | $26.74 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.30 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $23.53 | 2020-2022 | |
| Recor Medical INC | $22.40 | 2025 | Paradise Ultrasound Renal Denervation System |
| Ani Pharmaceuticals, INC. | $22.39 | 2025 | Purified Cortrophin Gel |
| Dexcom, INC. | $20.09 | 2024 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $19.88 | 2023 | Nocdurna, Tlando, Xyosted |
| Axonics, INC. | $14.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjaykumar Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.